Fusion induced reversal of dendritic cell maturation: An altered expression of inflammatory chemokine and chemokine receptors in dendritomas

Oncology Reports

Volumn 23, Issue 2, 2010, Pages 545-550

  Branham O'Connor, Melissa ^a   Li, Jinhua ^a   Kotturi, Hari S R ^a   Yu, Xianzhong ^a   Wagner, Thomas E ^a   Wei, Yanzhang ^a  

^a CLEMSON UNIVERSITY   (United States)

Author keywords

Chemokines; Dendritic cell fusion; Dendritoma; Microarray; Real time PCR

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; DENDRITIC CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL FUSION; CELL LYSATE; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; DENDRITIC CELL; DENDRITIC CELL SARCOMA; DENDRITOMA; FEMALE; GENE CONTROL; GENE EXPRESSION; GENOTYPE; IMMUNE RESPONSE; LYMPH NODE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ANIMALS; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CELL EXTRACTS; CELL FUSION; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINES; DENDRITIC CELLS; FEMALE; GENE EXPRESSION PROFILING; HYBRIDOMAS; IMMUNITY, CELLULAR; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, CHEMOKINE;

EID: 76649093647     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000668     Document Type: Article

References (36)

1. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998.
2. Hart DN: Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90: 3245-3287, 1997.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ and Schreiber RD: Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998, 2002.
4. Ullrich E, Menard C, Flament C, Terme M, Mignot G, Bonmort M, Plumas J, Chaperot L, Chaput N and Zitvogel L: Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev 19: 79-92, 2008.
5. Banchereau J and Steinman RM: Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109: 1519-1526, 2002.
6. Steinman RM and Hemmi H: Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 311: 17-58, 2006.
7. Schuler G, Schuler-Thurner B and Steinman RM: The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15: 138-147, 2003.
8. Svane IM, Soot ML, Buus S and Johnsen HE: Clinical application of dendritic cells in cancer vaccination therapy. APMIS 111: 818-834, 2003.
9. Ward S, Casey D, Labarthe MC, Whelan M, Dalgleish A, Pandha H and Todryk S: Immunotherapeutic potential of whole tumor cells. Cancer Immunol Immunother 51: 351-357, 2002.
10. Shimizu K, Kuriyama H, Kjaergaard J, Lee W, Tanaka H and Shu S: Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 27: 265-272, 2004.
11. Haigh P, Difronzo L, Gammon G and Morton DL: Vaccine therapy for patients with melanoma. Oncology 13: 1561-1574, 1999.
12. Holmes LM, Li J, Sticca RP, Wagner TE and Wei Y: A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dendritomas. J Immunother 24: 122-129, 2001.
13. Li J, Holmes LM, Franek KJ, Burgin KE, Wagner TE and Wei Y: Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 50: 456-462, 2001.
14. Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J, Evans L, Smith SJ, Stephenson JJ and Wagner TE: Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 28: 585-593, 2006.
15. Wei YC, Sticca RP, Li J, Holmes LM, Burgin KE, Jakubchak S, Bouton-Verville H, Williamson J, Meyer K, Evans L, Martin J, Stephenson JJ, Trocha S, Smith S and Wagner TE: Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: a pilot study. Oncol Rep 18: 665-671, 2007.
16. Gong JL, Koida S and Calderwood SK: Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev Vaccines 7: 1055-1068, 2008.
17. Steinman RM, Hawiger D and Nussenzweig MC: Tolerogenic dendritic cells. Annu Rev Immunol 21: 685-711, 2003.
18. Li J, Theofanous L, Stickel S, Bouton-Verville H, Burgin KE, Jakubchak S, Wagner TE and Wei Y: Transfer of in vitro expanded T lymphocytes after activation with dendritomas prolonged survival of mice challenged with EL4 tumor cells. Int J Oncol 31: 193-197, 2007.
19. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang AJ, Dahm P, Chao N, Gilboa E and Vieweg J: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115: 3623-3633, 2005.
20. Melief CJ: Cancer immunotherapy by dendritic cells. Immunity 29: 372-383, 2008.
21. Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST and Hwu P: Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 12: 5801-5808, 2006.
22. Fricke I and Gabrilovich DI: Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest 35: 459-483, 2006.
23. Ueno H, Fay J, Banchereau J and Palucka AK: Dendritic cell subsets as targets and vectors for vaccination: dendritic cells as cancer vaccines. In: Handbook of Dendritic Cells: Biology, Diseases and Therapies. Lutz MB, Romani N and Steinkasserer A (eds). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp1095-1115, 2006.
24. Sozzani S, Allavena P, Vecchi A and Mantovani A: Chemokines and dendritic cell traffic. J Clin Immunol 20: 151-160, 2000.
25. Sallusto F and Lanzavecchia A: Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev 177: 134-140, 2000.
26. Lutz MB, Kukutsch N, Ogilvie ALJ, Robner S, Koch R, Romani N and Shuler G: An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92, 1999.
27. Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, Mackay CR, Qin S and Lanzavecchia A: Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 28: 2760-2769, 1998.
28. Paglia P, Chiodoni C, Rodolfo M and Colombo MP: Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 183: 317-322, 1996.
29. Bernard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, Rimoldi D, Cerottini JC, Banchereau J and Palucka AK: Cross-priming of naïve CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 192: 1535-1543, 2000.
30. Yanagawa Y and Onoe K: CCR7 ligands induce rapid endocytosis in mature dendritic cells with concomitant up-regulation of Cdc42 and Rac activities. Blood 101: 4923-4929, 2003.
31. Li YL, Wu YG, Wang YQ, Li Z, Wang RC, Wang L and Zhang YY: Bone marrow-derived dendritic cells pulsed with tumor lysates induce anti-tumor immunity against gastric cancer ex vivo. World J Gastroenterol 14: 7127-7132, 2008.
32. Koido S, Hara E, Homma S, Torii A, Mitsunaga M, Yanagisawa S, Toyama Y, Kawahara H, Watanabe M, Yoshida S, Kobayashi S, Yanaga K, Fujise K and Tajiri H: Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J Immunol 178: 613-622, 2007.
33. Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T and Ohno T: Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 50: 337-344, 2001.
34. Sozzani S, Allavena P, D'Amico G, Luini W, Bianchi G, Kataura M, Imai T, Yoshie O, Bonecchi R and Mantovani A: Cutting edge: differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J Immunol 161: 1083-1086, 1998.
35. Vasir B, Wu Z, Crawford K, Rosenblatt J, Zarwan C, Bisssonnette A, Kufe D and Avigan D: Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodoexynucleotides, and anti-CD3/CD28 promote the expansion of activated tumor reactive T cells. J Immunol 181: 808-821, 2008.
36. Koido S, Hara E, Homma S, Mitsunaga M, Takahara A, Nagasaki E, Kawahara H, Watanabe M, Toyama Y, Yanagisawa S, Kobayashi S, Yanaga K, Fujise K, Gong J and Tajiri H: Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J Immunol 179: 4874-4883, 2007.